JNJ-39758979   Click here for help

GtoPdb Ligand ID: 8984

Synonyms: JNJ 39758979 | JNJ39758979
Immunopharmacology Ligand
Compound class: Synthetic organic
Comment: JNJ-39758979 is a selective histamine H4 receptor antagonist [4] with anti-inflammatory potential.
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 5
Hydrogen bond donors 2
Rotatable bonds 2
Topological polar surface area 81.06
Molecular weight 221.16
XLogP 0.97
No. Lipinski's rules broken 0
Click here for help
Canonical SMILES NC1CCN(C1)c1cc(nc(n1)N)C(C)C
Isomeric SMILES N[C@@H]1CCN(C1)c1cc(nc(n1)N)C(C)C
InChI InChI=1S/C11H19N5/c1-7(2)9-5-10(15-11(13)14-9)16-4-3-8(12)6-16/h5,7-8H,3-4,6,12H2,1-2H3,(H2,13,14,15)/t8-/m1/s1
No information available.
Summary of Clinical Use Click here for help
Phase 2a clinical trial results in patients with moderate atopic dermatitis are published in [2] which indicate that the study did not meet its primary end-point, and produced drug-induced agranulocytosis, explaining its termination. Phase 2 trial NCT00946569 in asthma patients has been completed.
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT00946569 A Study of the Safety and Effectiveness of JNJ-39758979 in the Treatment of Adults With Persistent Asthma Phase 2 Interventional Johnson & Johnson Pharmaceutical Research & Development, L.L.C.